Update of the Recommendations for the Determination of Biomarkers in Colorectal Carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2020 May 18

PMID 32418154

Citations 10

Authors

P Garcia-Alfonso

R Garcia-Carbonero

J Garcia-Foncillas

P Perez-Segura

R Salazar

R Vera

S Ramon Y Cajal

J Hernandez-Losa

S Landolfi

E Musulen

M Cuatrecasas

S Navarro

Affiliations

Soon will be listed here.

Abstract

In this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica-SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica-SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. Recently published information on the essential determination of KRAS, NRAS and BRAF mutations and the convenience of determining the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway and the study of NTRK fusions are also evaluated. From the pathological point of view, the importance of analysing the tumour budding and poorly differentiated clusters, and its prognostic value in CRC is reviewed, as well as the impact of molecular lymph node analysis on lymph node staging in CRC. The incorporation of pan-genomic technologies, such as next-generation sequencing (NGS) and liquid biopsy in the clinical management of patients with CRC is also outlined. All these aspects are developed in this guide, which, like the previous one, will remain open to any necessary revision in the future.

Citing Articles

Using of endoscopic polypectomy in patients with diagnosed malignant colorectal polyp - The cross-sectional clinical study.

Stojic V, Zdravkovic N, Nikolic-Turnic T, Zdravkovic N, Dimitrijevic J, Misic A Open Med (Wars). 2023; 18(1):20230811.

PMID: 37873541 PMC: 10590616. DOI: 10.1515/med-2023-0811.

Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer.

Bonilla C, Montenegro P, OConnor J, Hernando-Requejo O, Aranda E, Pinto Llerena J Cancers (Basel). 2023; 15(17).

PMID: 37686649 PMC: 10487247. DOI: 10.3390/cancers15174373.

Clinicopathological Profiles Associated with Discordant Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer.

Brozos-Vazquez E, Lago-Leston R, Covela M, de la Camara Gomez J, Fernandez-Montes A, Candamio S Cancers (Basel). 2023; 15(14).

PMID: 37509239 PMC: 10377339. DOI: 10.3390/cancers15143578.

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022).

Fernandez Montes A, Alonso V, Aranda E, Elez E, Garcia Alfonso P, Gravalos C Clin Transl Oncol. 2023; 25(9):2718-2731.

PMID: 37133732 PMC: 10425293. DOI: 10.1007/s12094-023-03199-1.

From Dukes-MAC Staging System to Molecular Classification: Evolving Concepts in Colorectal Cancer.

Banias L, Jung I, Chiciudean R, Gurzu S Int J Mol Sci. 2022; 23(16).

PMID: 36012726 PMC: 9409470. DOI: 10.3390/ijms23169455.

References

Hognas G, Kivinummi K, Kallio H, Hieta R, Ruusuvuori P, Koskenalho A . Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. Am J Surg Pathol. 2017; 42(1):103-115. DOI: 10.1097/PAS.0000000000000961. View

Gonzalez-Colunga K, Lino-Silva L, Salcedo-Hernandez R, Ruiz-Garcia E, Zepeda-Najar C . BRAF V600E Expression by Immunohistochemistry in Colon Cancer and Clinico-pathologic Features Associated with BRAF-Mutated Colonic Cancers in Mexican Patients. J Gastrointest Cancer. 2019; 51(1):35-40. DOI: 10.1007/s12029-018-00191-9. View

Sanz-Pamplona R, Berenguer A, Cordero D, Riccadonna S, Sole X, Crous-Bou M . Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS One. 2012; 7(11):e48877. PMC: 3492249. DOI: 10.1371/journal.pone.0048877. View

Martinez-Ciarpaglini C, Fernandez-Sellers C, Tarazona N, Rosello S, Huerta M, Roda D . Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens. Histopathology. 2019; 75(4):517-525. DOI: 10.1111/his.13900. View

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N . CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med. 2016; 374(3):211-22. PMC: 4784450. DOI: 10.1056/NEJMoa1506597. View

Sartore-Bianchi A, Loupakis F, Argiles G, Prager G . Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Ann Oncol. 2016; 27(8):1456-66. DOI: 10.1093/annonc/mdw191. View

Pietrantonio F, Di Nicolantonio F, Schrock A, Lee J, Morano F, Fuca G . RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol. 2018; 29(6):1394-1401. DOI: 10.1093/annonc/mdy090. View

Venderbosch S, Nagtegaal I, Maughan T, Smith C, Cheadle J, Fisher D . Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014; 20(20):5322-30. PMC: 4201568. DOI: 10.1158/1078-0432.CCR-14-0332. View

Yamanaka T, Oki E, Yamazaki K, Yamaguchi K, Muro K, Uetake H . 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. J Clin Oncol. 2016; 34(24):2906-13. DOI: 10.1200/JCO.2016.67.0414. View

10.

Cenaj O, Ligon A, Hornick J, Sholl L . Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. Am J Clin Pathol. 2019; 152(1):97-108. DOI: 10.1093/ajcp/aqz031. View

11.

Samaison L, Grall M, Staroz F, Uguen A . Microsatellite instability diagnosis using the fully automated Idylla platform: feasibility study of an in-house rapid molecular testing ancillary to immunohistochemistry in pathology laboratories. J Clin Pathol. 2019; 72(12):830-835. DOI: 10.1136/jclinpath-2019-205935. View

12.

DeStefanis R, Kratz J, Emmerich P, Deming D . Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. Curr Colorectal Cancer Rep. 2019; 15(2):61-69. PMC: 6528813. DOI: 10.1007/s11888-019-00430-6. View

13.

Garcia-Foncillas J, Tabernero J, Elez E, Aranda E, Benavides M, Camps C . Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br J Cancer. 2018; 119(12):1464-1470. PMC: 6288144. DOI: 10.1038/s41416-018-0293-5. View

14.

Taieb J, Kourie H, Emile J, Le Malicot K, Balogoun R, Tabernero J . Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. JAMA Oncol. 2017; 4(7):e173695. PMC: 6145739. DOI: 10.1001/jamaoncol.2017.3695. View

15.

Schrock A, Ouyang C, Sandhu J, Sokol E, Jin D, Ross J . Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019; 30(7):1096-1103. DOI: 10.1093/annonc/mdz134. View

16.

Murphy K, Zhang S, Geiger T, Hafez M, Bacher J, Berg K . Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn. 2006; 8(3):305-11. PMC: 1867601. DOI: 10.2353/jmoldx.2006.050092. View

17.

Franczak C, Dubouis L, Gilson P, Husson M, Rouyer M, Demange J . Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma. PLoS One. 2019; 14(2):e0212801. PMC: 6392303. DOI: 10.1371/journal.pone.0212801. View

18.

Dienstmann R, Salazar R, Tabernero J . Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015; 33(16):1787-96. DOI: 10.1200/JCO.2014.60.0213. View

19.

Garcia-Alfonso P, Garcia-Foncillas J, Salazar R, Perez-Segura P, Garcia-Carbonero R, Musulen-Palet E . Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2014; 17(4):264-73. DOI: 10.1007/s12094-014-1252-0. View

20.

Karapetis C, Khambata-Ford S, Jonker D, OCallaghan C, Tu D, Tebbutt N . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-65. DOI: 10.1056/NEJMoa0804385. View